Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Table 3 Breakdown of incremental costs according to treatment strategy in patients with HER2-negative breast cancer

Cost component	All patients		HR+ patients		TNBC patients
Cost component	Paclitaxel alone	Paclitaxel+ bevacizumab	Paclitaxel alone	Paclitaxel+ bevacizumab	Paclitaxel alone	Paclitaxel+ bevacizumab
Adverse events, EUR	10	82	11	85	8	74
Progression cost, EUR	22,588	29,319	24,700	35,752	14,871	17,980
Supportive care in PPS, EUR	786	1951	868	2147	529	1411
Administration cost, EUR	3542	4078	3772	4231	2982	3691
Drug cost, EUR	0	18,885	0	19,590	0	17,091

HR+ hormone receptor positive, PPS post-progression survival, TNBC triple negative breast cancer
All costs presented in 2016 EUR

ISSN: 1471-2407